Novartis

question unanswered wonder ask
Biotech

PTC and Novartis’ Huntington's data fail to convince investors

Investors wiped almost 20% off PTC’s share price amid doubts about the path to accelerated approval of the asset.
Nick Paul Taylor May 6, 2025 7:25am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Novartis pays $800M to buy Regulus for phase 3-ready kidney drug

Apr 30, 2025 9:30am
Broom sweep clean

Novartis axes osteoarthritis asset and radioligand therapy

Apr 29, 2025 5:24am
X ray illustration of a running person with pain in knee joint with blue background

Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset

Apr 16, 2025 2:55pm
The Top Line

A closer look at pharma's top R&D budgets

Apr 4, 2025 9:34am
parachute chutes

FDA rocked by leadership shake-ups—Chutes & Ladders

Apr 4, 2025 8:30am